RESULTS OF IMMUNOHISTOCHEMICAL STUDY OF THE THYROID GLAND IN GRAVES' DISEASE
Article Sidebar
Main Article Content
Аннотация:
Diffuse toxic goiter is a genetically determined autoimmune disease with a congenital defect of the immune system. With diffuse toxic goiter, the secretion of the thyroid hormones triiodothyronine (T3) and thyroxine (T4) increases, which often leads to thyrotoxicosis. Thyrotoxicosis is a clinical syndrome characterized by a persistent and prolonged increase in the level of thyroid hormones in the blood, which is caused by hyperstimulation of the thyroid gland by antibodies to the pituitary thyroid-stimulating hormone receptor. A characteristic sign of thyrotoxicosis is a significant increase in the level of basal metabolism with damage to all organs and systems [1,2,3]. The degree of proliferative activity of the follicular epithelium of the thyroid gland is important. Currently, to determine the degree of proliferation of the thyroid epithelium, an immunohistochemical research method is used [4,5]. Purpose of the study: to study the degree of proliferation of the follicular epithelium of the thyroid gland in diffuse toxic goiter.
Article Details
Как цитировать:
Библиографические ссылки:
Abramov, N.A., Fadeev, V.V. Conservative treatment of Graves' disease : principles, markers of relapse and remission // Problems of endocrinology. – 2005. – No. 6. - pp. 44-45.
Balabolkin , M.I. Modern approaches to the treatment of diffuse toxic goiter // Therapist. arch. – 1995. – No. 10. – P.15-18.
Valdina , E.A. Diseases of the thyroid gland. – St. Petersburg : Peter, 2001. – 368 p.
Kandror , V.I. Mechanisms of development of Graves' disease and the action of thyroid hormones // Clinical experimental thyroidology . – 2008. – No. 4. – P.26-34.
Shaposhnikov, V.M. Morphofunctional features of the thyroid gland in patients with diffuse toxic goiter // Klin . endocrinology . – 1991. – No. 1. – P.8-9. 300
Biodiversity, bioresources, biotechnology issues and public health in the North Caucasus region of Stavropol, 2019
Sheremeta, M.S. Clinical course of endocrine ophthalmopathy in Graves' disease depending on the effect of radioiodine therapy // Problems of Endocrinology. - 2011. - No. 3. - P. 17–20.
Aoki, Y. Serum TSH and total T4 in the United States population and their association with participant characteristics: National Health and Nutrition Examination Survey // Thyroid. – 2007. – Vol. 17. – P. 1211-1223.
Gullo, D. Levothyroxine monotherapy cannot guarantee euthyroidism in all athyreotic patients // PLoS One. – 2011. – Vol. 6. – Is. 8. – e22552. – P. 1-7.
Hovens, G.C.J. A bioluminescence assay for thyrotropin receptor antibodies predicts serum thyroid hormone levels in patients with, de novo Graves disease // Clin. Endocrinol. – 2006. – N. 4. – P. 429-435.
Noguchi, H. Surgical management of Grave’s disease, past and future // 12th Congress of Asian Association of Endocrine Surgeons, 2010. – March 23–24.
Improvement of tactical and technical aspects of surgical treatment of diffus toxic goiter. International Scientific Journal Theoretical & Applied Science 2021. Nishanov M.F., Aliboev M.R., Akhmadbekov B.O. 2021-y.